Common Contracts
7 similar Underwriting Agreement contracts by Pretium Resources Inc., Silver Standard Resources Inc, Cardiome Pharma Corp, others
COMMON SHARES CORREVIO PHARMA CORP. UNDERWRITING AGREEMENTUnderwriting Agreement • August 2nd, 2019 • Correvio Pharma Corp. • Pharmaceutical preparations • New York
COMMON SHARES PRETIUM RESOURCES INC. UNDERWRITING AGREEMENTUnderwriting Agreement • February 25th, 2016 • Pretium Resources Inc. • Metal mining • New York
Pretium Resources Inc., a corporation organized and existing under the laws of British Columbia (the “Company”), proposes to issue and sell, subject to the terms and conditions stated herein, to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 26,210,000 common shares (the “Firm Shares”), without par value. In addition, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, the Company grants to the Underwriters the option to purchase up to an additional 2,174,000 common shares (the “Additional Shares”). The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares”. CIBC World Markets Inc., RBC Dominion Securities Inc. and Scotia Capital Inc. are acting as lead managers (the “Lead Managers”) in connection with the offering and sale of the Shares contemplated herein (the “Offering”).
COMMON SHARES PRETIUM RESOURCES INC. UNDERWRITING AGREEMENTUnderwriting Agreement • May 8th, 2012 • Pretium Resources Inc. • Metal mining • New York
Pretium Resources Inc., a corporation organized and existing under the laws of British Columbia (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 4,830,000 common shares (the “Firm Shares”), without par value, and, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, up to an additional 724,500 common shares (the “Additional Shares”). The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares”. Scotia Capital Inc. is acting as lead manager (“Scotia” or the “Lead Manager”) in connection with the offering and sale of the Shares contemplated herein (the “Offering”).
SEABRIDGE GOLD INC. UNDERWRITING AGREEMENTUnderwriting Agreement • February 26th, 2010 • Seabridge Gold Inc • Gold and silver ores • New York
COMMON SHARES SILVER STANDARD RESOURCES INC. UNDERWRITING AGREEMENTUnderwriting Agreement • August 13th, 2009 • Silver Standard Resources Inc • Mineral royalty traders • New York
UBS SECURITIES CANADA INC. CREDIT SUISSE SECURITIES (USA) LLC DAHLMAN ROSE & CO., LLC DEUTSCHE BANK SECURITIES INC. MORGAN STANLEY & CO. INCORPORATED CIBC WORLD MARKETS INC. SCOTIA CAPITAL INC. BLACKMONT CAPITAL INC. GMP SECURITIES L.P. NATIONAL BANK FINANCIAL INC. SALMAN PARTNERS INC.
COMMON SHARES SILVER STANDARD RESOURCES INC. UNDERWRITING AGREEMENTUnderwriting Agreement • February 25th, 2009 • Silver Standard Resources Inc • Mineral royalty traders • New York
Silver Standard Resources Inc., a corporation organized and existing under the laws of British Columbia (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 5,450,000 common shares (the “Firm Shares”), without par value, and, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, up to an additional 817,500 common shares (the “Additional Shares”). The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares”. UBS Securities Canada Inc. is acting as lead manager (“UBS” or the “Lead Manager”) in connection with the offering and sale of the Shares contemplated herein (the “Offering”).
COMMON SHARES CARDIOME PHARMA CORP. UNDERWRITING AGREEMENTUnderwriting Agreement • January 19th, 2007 • Cardiome Pharma Corp • Pharmaceutical preparations • New York
Cardiome Pharma Corp., a corporation organized and existing under the laws of Canada (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 8,000,000 common shares (the “Firm Shares”), without par value, and, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, up to an additional 1,200,000 common shares (the “Additional Shares”). The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares”. Bear, Stearns & Co. Inc. (“Bear Stearns”) is acting as lead manager (the “Lead Manager”) in connection with the offering and sale of the Shares contemplated herein (the “Offering”).
